Cowen analyst Max Masucci lowered the firm’s price target on DermTech to $8 from $20 and keeps an Outperform rating on the shares. The analyst said the revenue shortfall is attributed more to market factors rather than management.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DMTK: